PE20220431A1 - Compuestos inhibidores de la masp y usos de estos - Google Patents

Compuestos inhibidores de la masp y usos de estos

Info

Publication number
PE20220431A1
PE20220431A1 PE2021001838A PE2021001838A PE20220431A1 PE 20220431 A1 PE20220431 A1 PE 20220431A1 PE 2021001838 A PE2021001838 A PE 2021001838A PE 2021001838 A PE2021001838 A PE 2021001838A PE 20220431 A1 PE20220431 A1 PE 20220431A1
Authority
PE
Peru
Prior art keywords
amino acid
natural amino
unnatural
natural
inhibitor compounds
Prior art date
Application number
PE2021001838A
Other languages
English (en)
Inventor
Donald Bierer
Ingo Flamme
Dmitry Zubov
Thomas Neubauer
Adrian Tersteegen
Cathleen Juhl
Marie Glatz
Jan Dreher
Simon Holton
Carsten Terjung
Lars Baumann
Thorsten Poethko
Jiancheng Xiong
Yibo Qiu
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of PE20220431A1 publication Critical patent/PE20220431A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Abstract

Esta referido a un peptido de Formula II: en donde: X1 es un aminoacido natural o un aminoacido no natural; q es 0 o 1; X2 es el aminoacido natural I; r es 0 o 1; X3 es el aminoacido natural C o el aminoacido antinatural L-Penicilamina (Pen); X4 es el aminoacido natural S; X5 es el aminoacido natural R o el aminoacido no natural N(5)-Metil-L-arginina ((Me)R); X6 es el aminoacido natural S; X7 es el aminoacido natural L o el aminoacido no natural L-tercButilalanina ((tBu)A); X8 es el aminoacido natural P o el aminoacido no natural LProlina (3,4-2H); X9 es el aminoacido natural P o el aminoacido no natural 2,3,3a,4,5,6,7,7a- Octahidroindol-2-acido carboxilico (Oic); X10 es el aminoacido natural I; X11 es L-N-metilcisteina ((N-Me)C) o L-penicilamina (Pen); X12 es el aminoacido natural I; X13 es el aminoacido natural P; s es 0 o 1; X14 es D, Q o E; t es 0 o 1. Estos compuestos inhibidores de la peptidasa de serina asociada a la lectina de union a la manosa (MBL) (MASP), y se emplean en el tratamiento y/o la prevencion de enfermedades renales y cardiovasculares y de lesiones por isquemia y reperfusion.
PE2021001838A 2019-05-07 2020-04-30 Compuestos inhibidores de la masp y usos de estos PE20220431A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019085791 2019-05-07
PCT/EP2020/062040 WO2020225095A1 (en) 2019-05-07 2020-04-30 Masp inhibitory compounds and uses thereof

Publications (1)

Publication Number Publication Date
PE20220431A1 true PE20220431A1 (es) 2022-03-29

Family

ID=70482659

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001838A PE20220431A1 (es) 2019-05-07 2020-04-30 Compuestos inhibidores de la masp y usos de estos

Country Status (15)

Country Link
US (2) US11667675B2 (es)
EP (1) EP3966226A1 (es)
JP (1) JP2022532069A (es)
KR (1) KR20220005556A (es)
CN (1) CN114585637A (es)
AR (1) AR119733A1 (es)
AU (1) AU2020268578A1 (es)
CA (1) CA3139209A1 (es)
CO (1) CO2021014755A2 (es)
IL (1) IL287753A (es)
MX (1) MX2021013616A (es)
PE (1) PE20220431A1 (es)
SG (1) SG11202111587VA (es)
TW (1) TW202108603A (es)
WO (1) WO2020225095A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4240750A1 (en) 2020-11-04 2023-09-13 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
EP4011904A1 (en) * 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2004216176B2 (en) 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
HUE024996T2 (en) 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
PL1753456T3 (pl) 2004-06-10 2017-01-31 Omeros Corporation Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
HUP0900319A2 (en) 2009-05-25 2011-01-28 Eotvos Lorand Tudomanyegyetem New peptides, method of producing therof and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN106977530A (zh) 2010-07-09 2017-07-25 拜耳知识产权有限责任公司 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
RU2709351C2 (ru) * 2012-06-18 2019-12-17 Омерос Корпорейшн Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений
AU2013292046C1 (en) 2012-07-20 2018-03-15 Bayer Pharma Aktiengesellschaft Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
WO2014144542A2 (en) 2013-03-15 2014-09-18 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
AU2014332021B2 (en) 2013-10-07 2020-05-07 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
SG11201610799WA (en) 2014-06-27 2017-01-27 Protagonist Therapeutics Inc Hepcidin and mini-hepcidin analogues and uses therof

Also Published As

Publication number Publication date
US20210246166A1 (en) 2021-08-12
CN114585637A (zh) 2022-06-03
US11667675B2 (en) 2023-06-06
CO2021014755A2 (es) 2021-11-19
CA3139209A1 (en) 2020-11-12
EP3966226A1 (en) 2022-03-16
AU2020268578A1 (en) 2022-02-03
KR20220005556A (ko) 2022-01-13
SG11202111587VA (en) 2021-11-29
US20240124522A1 (en) 2024-04-18
TW202108603A (zh) 2021-03-01
JP2022532069A (ja) 2022-07-13
IL287753A (en) 2022-01-01
WO2020225095A1 (en) 2020-11-12
AR119733A1 (es) 2022-01-05
MX2021013616A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
PE20220431A1 (es) Compuestos inhibidores de la masp y usos de estos
PE20210050A1 (es) Nuevos compuestos de sulfonamida carboxamida
PE20171332A1 (es) Inmunomoduladores
EA201990071A1 (ru) Композиция пептидной вакцины
PE20230370A1 (es) Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
PE20200678A1 (es) Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2)
CY1123477T1 (el) Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσων
BRPI0506494A (pt) compostos de silinano como inibidores de cisteìna protease
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
EA201990298A1 (ru) Способы и композиции для лечения рака
ATE553090T1 (de) Cathepsincysteinproteasehemmer
EA202190888A1 (ru) Пептид для применения в косметике
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
MX2016007407A (es) Peptidos resistentes a proteasa.
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
NZ736652A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
NZ732301A (en) Peptide compound, preparation method therefor, and application thereof
MX2020001761A (es) Analogo de peptido de oxintomodulina acilado.
PH12021551055A1 (en) Klk5 inhibitory peptide
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
PE20181293A1 (es) Plataforma de armazon de nudo de cistina